JP2021503486A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503486A5
JP2021503486A5 JP2020527899A JP2020527899A JP2021503486A5 JP 2021503486 A5 JP2021503486 A5 JP 2021503486A5 JP 2020527899 A JP2020527899 A JP 2020527899A JP 2020527899 A JP2020527899 A JP 2020527899A JP 2021503486 A5 JP2021503486 A5 JP 2021503486A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
diabetes
pancreatic
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020527899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/062023 external-priority patent/WO2019100062A1/en
Publication of JP2021503486A publication Critical patent/JP2021503486A/ja
Publication of JP2021503486A5 publication Critical patent/JP2021503486A5/ja
Pending legal-status Critical Current

Links

JP2020527899A 2017-11-20 2018-11-20 キナーゼ阻害剤化合物ならびに組成物および使用法 Pending JP2021503486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588792P 2017-11-20 2017-11-20
US62/588,792 2017-11-20
PCT/US2018/062023 WO2019100062A1 (en) 2017-11-20 2018-11-20 Kinase inhibitor compounds and compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2021503486A JP2021503486A (ja) 2021-02-12
JP2021503486A5 true JP2021503486A5 (cg-RX-API-DMAC10.html) 2022-01-04

Family

ID=66539149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020527899A Pending JP2021503486A (ja) 2017-11-20 2018-11-20 キナーゼ阻害剤化合物ならびに組成物および使用法

Country Status (7)

Country Link
US (1) US11547712B2 (cg-RX-API-DMAC10.html)
EP (1) EP3717475B1 (cg-RX-API-DMAC10.html)
JP (1) JP2021503486A (cg-RX-API-DMAC10.html)
CN (1) CN111936490A (cg-RX-API-DMAC10.html)
AU (1) AU2018368790A1 (cg-RX-API-DMAC10.html)
CA (1) CA3084581A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019100062A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
WO2025231425A1 (en) * 2024-05-03 2025-11-06 Biosplice Therapeutics, Inc. 4-aminopyrrolo[2,l-f][l,2,4]triazines and preparation and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
DK1789044T3 (da) 2004-09-06 2010-12-06 Basilea Pharmaceutica Ag Phenylaminopyridiner og phenylaminopyraziner
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
BRPI0807961A2 (pt) 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
GB0705566D0 (en) 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US20100173931A1 (en) 2009-01-06 2010-07-08 Osteogenex Inc. Harmine derivatives for reducing body weight
WO2010123583A2 (en) 2009-04-24 2010-10-28 University Of Tennessee Research Foundation 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof
AU2010247412A1 (en) 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
WO2010135589A2 (en) 2009-05-20 2010-11-25 Sakura Properties, Llc Dietary supplement drink for delivery of resveratrol and other polyphenols
JP2011006408A (ja) * 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
CN102791134B (zh) 2009-12-04 2015-04-22 魄金莱默有限公司 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法
WO2011075665A2 (en) 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20130102627A1 (en) 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
WO2011133795A2 (en) 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US9168247B2 (en) 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
AU2011290123B2 (en) 2010-08-09 2016-11-10 Takeda Pharmaceutical Company Limited Method of producing pancreatic hormone-producing cells
US20130165474A1 (en) 2010-08-17 2013-06-27 Travis Dunckley Compounds that inhibit tau phosphorylation
KR102006749B1 (ko) 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
CN103070862A (zh) 2011-10-25 2013-05-01 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用
WO2013119518A1 (en) 2012-02-06 2013-08-15 The Regents Of The University Of California Small molecules for islet expansion
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
JP2016500080A (ja) 2012-11-26 2016-01-07 新疆華世丹薬物研究有限責任公司 ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途
JPWO2014058080A1 (ja) 2012-11-30 2016-09-05 国立研究開発法人理化学研究所 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット
CN102977096B (zh) 2012-12-07 2014-12-17 中国药科大学 具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药
MX2015007097A (es) 2012-12-10 2015-09-29 Hoffmann La Roche Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
US20150174034A1 (en) * 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
SI2968284T1 (sl) 2013-03-14 2021-08-31 Osteoqc Inc. Alkil-amin harmin derivati za pospeševanje rasti kosti
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
CN105555785B (zh) * 2013-06-18 2019-03-01 4Sc股份公司 作为dyrk激酶抑制剂的2,3-二氢苯并呋喃-5-基化合物
GB2519623A (en) 2013-06-18 2015-04-29 4Sc Discovery Gmbh Method of inhibiting DYRK1B
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
ES2529865B8 (es) 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
SI3057959T1 (en) 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US11332716B2 (en) 2015-07-27 2022-05-17 The Regents Of The University Of California Methods and compositions for producing pancreatic beta cells
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN105884767B (zh) 2015-11-24 2018-01-19 西华大学 9‑位取代的吡啶并[3,4‑b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10487087B2 (en) 2015-12-30 2019-11-26 Vanderbilt University Positive allosteric modulators of the GLP-1 receptor
WO2017168245A1 (en) 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
WO2017197151A1 (en) 2016-05-11 2017-11-16 Emory University Phosphotidylinositol 3-kinase inhibitors
WO2018081401A1 (en) 2016-10-26 2018-05-03 Ichan School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124353A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Similar Documents

Publication Publication Date Title
US10238636B2 (en) Methods of treating liver disease
AU2013321235B2 (en) RET inhibitor
JP2021518413A5 (cg-RX-API-DMAC10.html)
JP2021507906A (ja) 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
JP2006508970A5 (cg-RX-API-DMAC10.html)
RU2016100363A (ru) Композиции и способы лечения анемии
EP2903645A2 (en) Treatment of ocular disorders
JP2022518456A (ja) 置換多環式カルボン酸、その類似体、およびそれらの使用法
CN104797581A (zh) 杂芳基炔烃化合物及其应用
JP2022515650A5 (cg-RX-API-DMAC10.html)
JP2001048786A (ja) 三環式ヘテロアリール誘導体
JP2025526003A (ja) ピペラジン化合物とpd-1阻害剤またはpd-l1阻害剤との組成物、および腫瘍治療におけるその使用
JP2022515652A5 (cg-RX-API-DMAC10.html)
US20240245682A1 (en) Alpha-v-beta-8 integrin inhibitors and uses thereof
CN116390757A (zh) 用于治疗肿瘤的药物组合物
EP4423075B1 (en) Ccr6 receptor modulators
HUT62577A (en) Process for producing imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising same
CN113214230B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CA3235910A1 (en) Ccr6 receptor modulators
TW202519233A (zh) 一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途
KR102068860B1 (ko) Vegfr-3 저해제의 간세포암 치료를 위한 용도
JP2019501971A5 (cg-RX-API-DMAC10.html)
EP2862573A1 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
WO2004089930A1 (en) 4-fluoroquinolone derivatives and their use as kinase inhibitors
EA026297B1 (ru) Комбинированная терапия рака яичников